Compare GLP & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLP | ANIP |
|---|---|---|
| Founded | 2005 | 2001 |
| Country | United States | United States |
| Employees | 4700 | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | N/A | 1999 |
| Metric | GLP | ANIP |
|---|---|---|
| Price | $49.29 | $78.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $46.00 | ★ $110.00 |
| AVG Volume (30 Days) | 43.2K | ★ 315.6K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.40% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 1.28 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $64.13 | $21.01 |
| Revenue Next Year | $11.74 | $17.59 |
| P/E Ratio | ★ $23.28 | $61.90 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $39.58 | $56.71 |
| 52 Week High | $56.51 | $99.50 |
| Indicator | GLP | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 59.86 | 45.10 |
| Support Level | $48.78 | $77.46 |
| Resistance Level | $52.95 | $83.58 |
| Average True Range (ATR) | 1.67 | 3.12 |
| MACD | 0.14 | -0.46 |
| Stochastic Oscillator | 74.68 | 15.12 |
Global Partners LP is a limited partnership that acts as a midstream logistics and marketing company. It is mainly engaged in purchasing, selling, storing and logistics of transporting petroleum and related products. The company owns and operates and control terminal networks of refined petroleum products and renewable fuels in Massachusetts, Maine, Connecticut, Vermont, and other places. It distributes gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, natural gas and propane to wholesalers, retailers and commercial customers. The company operates through three segments i.e. Wholesale, Gasoline Distribution and Station Operations and Commercial. It generates maximum revenue from the GDSO segment.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.